MaxCyte Q1 2024 GAAP EPS $(0.09) Beats $(0.12) Estimate, Sales $11.342M Beat $7.462M Estimate
MaxCyte Q1 2024 GAAP EPS $(0.09) Beats $(0.12) Estimate, Sales $11.342M Beat $7.462M Estimate
MaxCyte 2024年第一季度GAAP每股收益美元（0.09美元）超過預期（0.12美元），銷售額爲11342萬美元，超過預期的74.62億美元
MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.12) by 25 percent. This is a 18.18 percent increase over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $11.342 million which beat the analyst consensus estimate of $7.462 million by 52.00 percent. This is a 32.25 percent increase over sales of $8.576 million the same period last year.
MaxCyte（納斯達克股票代碼：MXCT）公佈的季度虧損爲每股0.09美元，比分析師普遍預期的0.12美元（0.12美元）高出25％。這比去年同期每股虧損0.11美元（0.11美元）增長了18.18％。該公司公佈的季度銷售額爲1134.2萬美元，比分析師共識估計的746.2萬美元高出52.00％。這比去年同期的857.6萬美元的銷售額增長了32.25％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。